RMD Earnings & Financial Statements
ResMed Inc.
$240.63
+$5.34(+2.27%)
76
Overall
95
Value
81
Tech
52
Quality
Market Cap
$33.06B
Volume
181.88K
52W Range
$180.27 - $277.67
Target Price
$238.47
RMD earnings and financial statements: ResMed Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
RMD Annual Financial Statements
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $5.65B | $5.15B | $4.69B | $4.22B | $3.58B |
| Cost of revenue | -$2.17B | -$2.06B | $2.00B | $1.84B | $1.51B |
| Operating income | $1.89B | $1.69B | $1.32B | $1.13B | $1.00B |
| EBITDA | $1.32B | $1.36B | $1.53B | $1.35B | $1.18B |
| Net income | $1.52B | $1.40B | $1.02B | $897.56M | $779.44M |
| EPS (diluted) | $10.43 | $9.51 | $6.92 | $6.09 | $5.30 |
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total assets | $8.97B | $8.17B | $6.87B | $6.75B | $5.10B |
| Total liabilities | $2.38B | $2.21B | $2.01B | $2.62B | $1.74B |
| Shareholders’ equity | $6.59B | $5.97B | $4.86B | $4.13B | $3.36B |
| Cash and equivalents | $1.47B | $1.21B | $238.36M | $227.89M | $273.71M |
| Long-term debt | $536.83M | $811.41M | $838.76M | $1.55B | $885.78M |
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating cash flow | $1.81B | $1.75B | $1.40B | $693.30M | $351.15M |
| Capital expenditure | -$158.50M | -$89.86M | -$114.86M | -$134.00M | -$156.04M |
| Free cash flow | $1.65B | $1.66B | $1.29B | $559.30M | $195.11M |
| Dividends paid | $349.66M | $310.88M | $282.32M | $258.28M | $245.34M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RMD | $240.63 | +2.3% | 181.88K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |